BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU

Key Takeaways Bayer gained approval for Lynkuet to treat moderate to severe vasomotor symptoms in the EU. Approval is based on positive OASIS studies that met all primary and key secondary endpoints.The nod broadens Bayer's portfolio and adds to momentum alongside Nubeqa and Kerendia.Bayer (BAYRY) obtained European Commission approval for elinzanetant for the treatment of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) associated with menopause or caused by adjuvant endocrine therapy ...